NPS+(¹Ì±¹) - Àü¸³¼±¾Ï
NPS+ (US) - Prostate Cancer
»óǰÄÚµå : 1803887
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,195,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÌ º¸°í¼­´Â Àü¸³¼±¾Ï Ä¡·á¿¡ ´ëÇÑ ¹Ì±¹ Á¾¾çÇÐÀÚµéÀÇ °ßÇØ¸¦ Á¶»çÇϰí ÁÖ¿ä Ä¡·áÁ¦ÀÇ ºê·£µå Ãæ¼ºµµ, ¸¸Á·µµ, ½ÃÀå Á¡À¯À²¿¡ ´ëÇØ »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù. ÀÇ»çÀÇ Ã³¹æ °áÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎ, ÁÖ¿ä ºê·£µåÀÇ ºñ±³ ¼º´É, ÀÓ»óÀÇÀÇ ¸¶À½¿¡ °¡Àå ¿Í ´ê´Â ¸Þ½ÃÁö¿¡ ´ëÇØ Á¶»çÇϰí ÀÖ½À´Ï´Ù.

NPS+(Net Promoter Score) ÁöÇ¥¿Í Á¤¼ºÀû Çǵå¹éÀ» ÅëÇØ ºê·£µå °ÇÀü¼º, ¸¸Á·µµ ¿äÀÎ, ºê·£µå°¡ Àüȯ¿¡ ¿µÇâÀ» ¹Þ±â ½¬¿î ¿µ¿ª µî ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© Á¦¾à Àü¹®°¡ÀÇ Àü·«Àû ÀÇ»ç°áÁ¤À» Áö¿øÇÕ´Ï´Ù.

ÁÖ¿ä Áú¹®

ÁÖ¿ä ºê·£µå

  • Akeega (abiraterone acetate/niraparib)
  • Lynparza (olaparib)
  • Nubeqa (darolutamide)
  • Orgovyx (relugolix)
  • Pluvicto (lutetium-177 vipivotide tetraxetan)
  • Rubraca (rucaparib)
  • Talzenna (talazoparib)
  • Xofigo (radium-223 chloride
  • Xtandi (enzalutamide)

Á¶»ç ¹æ¹ý:

FirstWord Reports´Â 300¸¸ ¸í ÀÌ»óÀÇ Àǻ簡 È®ÀÎµÈ ¼¼°è ÃÖ´ë ÀÇ»ç µð·ºÅ丮ÀÎ LiMATMÀ» ÅëÇØ ¼±º°µÈ ÀÇ»çµéÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¤·®Àû ¼³¹®Á¶»ç¸¦ ÅëÇØ °³¹ßµÇ¾ú½À´Ï´Ù. °¢ ÀÇ»ç´Â ¾ö°ÝÇÑ ½É»ç ±âÁØ¿¡ µû¶ó ½ÅÁßÇÏ°Ô ¼±Á¤µÇ¾î ¼öÁýµÈ ÀλçÀÌÆ®ÀÌ ÀûÀýÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç, ÃÖ°í ¼öÁØÀÇ ÀÇ·á Àü¹®°¡ÀÇ Áø½É°ú °æÇèÀ» ¹Ý¿µÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. Á¶»ç °á°ú´Â ÇØ¼®Çϱ⠽¬¿î ±×·¡ÇÁ·Î Ç¥½ÃµÇ¾î µ¥ÀÌÅ͸¦ ºü¸£°Ô ÆÄ¾ÇÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù. FirstWord Reports´Â LiMATMÀÇ ¹æ´ëÇÑ µµ´Þ ¹üÀ§¿Í Á¤È®¼ºÀ» Ȱ¿ëÇÏ¿© Àü·«Àû °èȹ ¼ö¸³À» À§ÇÑ Å¹¿ùÇÑ µ¥ÀÌÅÍ ±â¹Ý ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á ºü¸£°Ô º¯È­ÇÏ´Â ÇコÄɾî ȯ°æ¿¡¼­ ÇÑ ¹ß ¾Õ¼­ ³ª°¥ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¿ì¸® º¸°í¼­ÀÇ Æ¯Â¡Àº?

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿À Á¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀº °í°´ÀÌ »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÒ ¼ö ÀÖµµ·Ï ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÃÖ°í ¼öÁØÀÇ Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÀλçÀÌÆ®¸¦ ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇÐÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. 40°³°¡ ³Ñ´Â ¿ªµ¿ÀûÀÎ Áúȯ ¿µ¿ªÀ» Ä¿¹öÇϸç, KOL ÀλçÀÌÆ®¿Í Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ´ç»çÀÇ º¸°í¼­´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅÍ ±â¹ÝÀÇ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report examines US oncologists' perspectives on prostate cancer therapies, providing a detailed analysis of brand loyalty, satisfaction, and market share among leading treatments. It explores the factors influencing physician prescribing decisions, the comparative performance of major brands, and the messages that resonate most with clinicians.

Through Net Promoter Score (NPS+) metrics and qualitative feedback, the report offers actionable insights into brand health, drivers of satisfaction, and areas where brands may be vulnerable to switching, supporting pharmaceutical professionals in strategic decision-making.

Key Questions Answered:

Key Brands:

  • Akeega (abiraterone acetate/niraparib)
  • Lynparza (olaparib)
  • Nubeqa (darolutamide)
  • Orgovyx (relugolix)
  • Pluvicto
    (lutetium-177 vipivotide tetraxetan)
  • Rubraca (rucaparib)
  • Talzenna (talazoparib)
  • Xofigo (radium-223 chloride
  • Xtandi (enzalutamide)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â